- The major vendors in the Global Acne Market 2014-2018 include Actavis plc, Allergen Inc., Galderma S.A., Stiefel Laboratories Inc. and Valeant Pharmaceuticals International Inc.
London, 28 October 2014: TechNavio, an independent tech-focused global research firm, has announced the publication of its market research report on the Global Acne Market 2014-2018. One major trend emerging in the market is the increased focus on combination therapies, which have led to enhanced safety and efficacy profiles, and have increased patient compliance to the medication. The market is expected to witness an improvement in its growth rate and post a CAGR of 4.07 percent during the period 2013-2018.
The Global Acne market is currently served by the marketed drugs. While the US dominates the Global Acne market, China and India are anticipated to play a significant role in the market within the forecast period. A moderate increase in the market is credited to the market being overloaded with generics and increased approval of alternative therapies such as PDT and UV/blue light therapy.
“Currently, the available drugs in the market are not capable of curing the disease completely. They only provide symptomatic relief by reducing lesions to almost 50 percent but do not suppress their re-occurrence,” says Faisal Ghaus, Vice President of TechNavio Research.
“The development and subsequent launch of drugs with a novel mechanism of action to target acne, with relatively high efficacy and safety profiles, are very important to overcome the significant unmet need posed by the existing market.”
To define the market conditions in the next 3-4 years, TechNavio analysts have conducted in-depth analysis of the impact of market drivers, challenges and trends featuring data on product segmentations, vendor shares, growth rate by revenue and an evaluation of the different buying criteria in the order of importance.
https://www.technavio.com/%3Cp%3EIf%20you%20are%20interested%20in%20more%…
